Wednesday, February 14, 2018

Courtesy The Oh-So-Kind Anon: Nice Reversal, At Swords, Ireland, Since November 2013...


As we somberly reported back in November of 2013, this entire Merck Ireland facility was slated to close forever.

Between the ongoing, and dragged out Brexit shifts, and improving bioscience (immuno-oncology) pipeline deliveries, Merck's MSD subsidiaries are now expanding in and near London, as well as in Dublin -- one of my favorite places on the green Earth. Smile. Here's the bit, from Irish Times:

. . . .MSD’s US parent, the drug giant Merck, is looking to ramp up global manufacturing capacity for its blockbuster cancer therapy Keytruda. At present the group has only one immuno-oncology manufacturing base, with the rest of its supplies delivered by contract manufacturing partners.

Ger Brennan, managing director of MSD Human Health, said the company expected “significant growth” in immuno-oncology over the coming years.

“We need to have confidence in supply,” he said.

MSD expects the new facility to be operational in 2021 and fully certified by 2022. “It’s a bold statement by MSD,” said Mr Brennan, “but that’s our target.”

The Swords investment will be a “significant component” of the €4 billion capital expenditure plan outlined by the US group earlier this month, Mr Brennan said, although MSD did not disclose the amount of its investment. . . .


Now you know -- smiling, as quite leprechaun-like. . . I vanish.

नमस्ते

No comments: